Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease and Type 2 Diabetes: A Narrative Review.
Type 2 diabetes is the leading cause of chronic kidney disease worldwide, and for decades renin-angiotensin-system (RAAS) blockade was the only proven strategy to slow its progression. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have since been shown to slow kidney function decline and reduce cardiorenal events t...